What is this medicine used for?
FDA-approved uses
- Schizophrenia — Adults and pediatric patients aged 13 years and older. Pediatric dosing has a lower maximum and separate titration.Vraylar oral capsules.
- Acute manic or mixed episodes associated with bipolar I disorder — Adults and pediatric patients aged 10 years and older. Age-specific schedules and maximum doses apply.Vraylar oral capsules.
- Depressive episodes associated with bipolar I disorder — Adults. Adult bipolar depression; pediatric effectiveness is not established.Vraylar oral capsules.
- Adjunctive treatment of major depressive disorder — Adults. Added to an antidepressant; not an approval for pediatric depression or antidepressant replacement.Vraylar oral capsules.
What should I expect?
Fuller benefit can take several weeks or longer. Because active breakdown products leave the body slowly, the effects of a new dose may continue to develop for weeks.
Report new restlessness or movement symptoms even if they start well after a dose change. Continue planned monitoring after reductions or stopping, and contact the prescriber if improvement is not developing.
How do I take it safely?
Take once daily with or without food. Follow the exact dose for the diagnosis and age; adult schedules must not be transferred to children.
Monitor weight, blood pressure, glucose, blood fats, restlessness and other movement changes. Blood-cell counts may be needed for people with previous low counts. Continue monitoring for several weeks after dose changes or stopping.
Have all medicines checked. Certain antibiotics, antifungals and other medicines that inhibit CYP3A4 require substantial dose changes; CYP3A4 inducers are not recommended. Pediatric interaction instructions differ from adult instructions.
Discuss severe kidney or liver disease, previous seizures, heart disease, swallowing problems, dehydration or falls. Severe kidney or liver impairment is not a recommended-use setting in the current label.
Alcohol and sedating or blood-pressure medicines may add impairment or fainting. Do not drive until you know the effects, and avoid overheating or dehydration.
For a missed dose, take it when remembered unless the next is close, then skip it; never double. Plan stopping or switching with the prescriber rather than relying on its long persistence to protect against missed treatment.
Discuss pregnancy planning and breastfeeding. Drug effects may persist after stopping; late-pregnancy antipsychotic exposure can affect newborn movement, feeding or breathing. The boxed dementia mortality warning remains applicable.
Do not use after a known allergy to cariprazine or product ingredients.
What side effects should I know about?
- AkathisiaAkathisiaAkathisia is distressing inner restlessness with a strong urge to move, sometimes caused by medication. It may lead to pacing, rocking or difficulty sitting still.Anxiety involves fear or worry; agitation is a broader state of distress or restlessness. These can overlap with akathisia, but the compelling urge to move is an important clue. Tell your prescriber promptly about new or worsening restlessness so the cause can be assessed., other movement symptoms or restlessness.
- Nausea, sleep changes, indigestion, constipation, fatigue or dizziness depending on indication.
Tell your prescriber about effects that are persistent, troublesome, or interfere with daily life.
Looking for more detailed information?
The official medicine information lists more side effects, safety advice and product instructions.
- View FDA Prescribing Information (PDF) (opens in a new tab)Vraylar: current prescribing information
Which warning signs need help?
- FDA boxed warningsFDA boxed warningAn FDA boxed warning is a prominently displayed warning in US prescribing information about especially serious risks, which may include death or serious injury. It is sometimes called a black-box warning.It highlights information that needs particular attention when deciding whether and how to use a medicine. A boxed warning does not mean the medicine is banned or that everyone will experience the harm. Read the medicine-specific warning and discuss it with your prescriber. address increased mortality in older adults with dementia-related psychosisPsychosisPsychosis describes symptoms that affect a person’s ability to tell what is real. These can include hallucinations, delusions and disorganized thinking or speech.Psychosis can occur with different mental or physical health conditions, some medicines or substance use. It does not automatically mean schizophrenia. New symptoms need prompt professional assessment. and increased suicidal thoughts and behaviors in pediatric and young adult antidepressant-treated patients. Vraylar is not approved for dementia-related psychosisPsychosisPsychosis describes symptoms that affect a person’s ability to tell what is real. These can include hallucinations, delusions and disorganized thinking or speech.Psychosis can occur with different mental or physical health conditions, some medicines or substance use. It does not automatically mean schizophrenia. New symptoms need prompt professional assessment.. Monitor all patients treated for depression for worsening mood or suicidal thinking; the newer pediatric schizophrenia and mania approvals do not establish pediatric depression approval.
- High fever with severe muscle stiffness, confusion or unstable pulse can be neuroleptic malignant syndrome; get emergency care.
- Report new involuntary movements promptly because they can persist. Severe restlessness, falls, fainting, fever with infection symptoms or swallowing difficulty also needs assessment.
- Marked thirst, frequent urination, severe weakness or confusion may signal high blood sugar; seek prompt assessment. Adverse effects can appear weeks after a dose change.
- New suicidal thoughts or a severe mood or behavior change needs immediate clinical contact; get emergency help if someone cannot stay safe.
- Get emergency help for trouble breathing, swelling of the tongue or throat, collapse, a seizure or inability to wake. Suspected overdose needs immediate poison-center or emergency advice; do not wait for symptoms.
What else should I know to stay safe?
- Do not use after cariprazine or ingredient allergy. Severe kidney or liver impairment is not a recommended-use setting. Certain enzyme-blocking medicines require substantial dose changes; enzyme-inducing medicines are not recommended, and pediatric interaction instructions differ from adult instructions.
- Monitor weight, blood pressure, glucose, blood fats and movements; previous low white-cell counts may require blood tests. Review seizures, heart disease, swallowing problems and falls. Avoid alcohol, unreviewed sedatives, dehydration, overheating and driving while impaired.
- Plan stopping or switching and continue monitoring for several weeks because active breakdown products persist. Discuss pregnancy planning and breastfeeding; effects can remain after stopping, and late-pregnancy exposure can affect newborn movement, feeding or breathing.
Urgent help and crisis support · Emergency & Crisis Resources (US)
What can help day to day?
- A delayed side effect can still be related to a recent dose change. Cariprazine’s active breakdown products remain in the body for weeks.
- A lower dose may be appropriate for one diagnosis than another. The maximum used for schizophrenia is not the maximum for depression.
- Feeling driven to move may be a medication effect called akathisiaAkathisiaAkathisia is distressing inner restlessness with a strong urge to move, sometimes caused by medication. It may lead to pacing, rocking or difficulty sitting still.Anxiety involves fear or worry; agitation is a broader state of distress or restlessness. These can overlap with akathisia, but the compelling urge to move is an important clue. Tell your prescriber promptly about new or worsening restlessness so the cause can be assessed.. Describing it clearly helps the prescriber distinguish it from anxiety or worsening illness.
How does it work?
Cariprazine changes how brain cells respond to dopamine and serotonin, two chemical messengers. It partly activates some receptors, the proteins that receive those messages, and blocks others. Its effects also depend on active substances made as the body processes it, which can remain present for a long time.
How was this medicine developed?
Vraylar first received FDA approval in 2015. Later approvals added adult depression uses and, in December 2025, schizophrenia from age 13 and bipolar I manic or mixed episodes from age 10. Those pediatric changes did not approve pediatric depression treatment.
How do I say the name?
Cariprazine: kar-ip-rah-zeen. Capital letters show the stressed syllable.
Sources and References
Sources support the U.S. products described here. Product instructions can differ; use the information supplied with your own medicine.
- Vraylar: current prescribing information
- Vraylar: FDA approval and supplement history
- Cariprazine: patient medicine information
- Vraylar: FDA label with current pediatric populations
- Vraylar: Package Insert / Prescribing Information / MOA
- Rexulti: current prescribing information
- Cariprazine: verified neutral parent, PubChem CID 11154555
- A qualitative investigation into the effects of akathisia - Health Research Authority
- Extrapyramidal side effects- Management
- Anxiety and panic attacks - NHS
- Agitation: MedlinePlus Medical Encyclopedia
- Frequently Asked Questions about Labeling for Prescription Medicines | FDA
- NIMH: Understanding psychosis
Giving medicine safely to children: family guide (PDF, 3 pages)

